Hepion Pharmaceuticals Inc (HEPA)

[Bertsllc]

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial.
Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.
As previously disclosed, the trial achieved all primary endpoints.
Related Content:Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
Price Action: HEPA shares are up 16.9% at $1.94 during the premarket session on the last check Monday.